Harris, M. Scott
4 papers on CoChatORCID 0000-0001-5141-5773
Most cited papers
- Verified
Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis
Nestor, J. J., Parkes, D., Feigh, M., Suschak, J. J., & Harris, M. S. (2022) · Scientific Reports
Liver Disease Diagnosis and TreatmentLiver physiology and pathology
Cited by 53
- Verified
Bimodal Release Ondansetron Improves Stool Consistency and Symptomatology in Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Trial
Plasse, T. F., Barton, G., Davidson, E., Abramson, D., Kalfus, I., Fathi, R., Raday, G., & Harris, M. S. (2020) · American Journal of Gastroenterology
Gastrointestinal motility and disordersInflammatory Bowel Disease
Cited by 40
- Verified
334-OR: pemvidutide (ALT-801), a balanced (1: 1) GLP-1/glucagon dual receptor agonist, induces rapid and marked weight loss without the need for dose titration in people with overweight/obesity
KLEIN, S., NESTOR, J. J., HARRIS, M. S., SUYUNDIKOV, A., CASPER, R., STEELE, S. M., PAYNE, J. D., KRISHNAN, V., ROBERTS, M. S., & BROWNE, S. K. (2022) · Diabetes
Pharmacology and Obesity TreatmentDiabetes Treatment and Management
Cited by 21
- Verified
Pemvidutide, a glp-1/glucagon dual receptor agonist, significantly reduces liver fat, fibro-inflammation, and body weight in patients with non-alcoholic fatty liver disease: a 24-week multicenter, randomized, double-blind, placebo-controlled trial
Harrison, S., Tomah, S., Suschak, J., Roberts, S., Yang, J., He, L., Georges, B., Rodwell-Green, L., Brown, R., Harris, M. S., et al. (2023) · Journal of Hepatology
Liver Disease Diagnosis and TreatmentDiabetes Treatment and Management
Cited by 4
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free